Entera Bio Ltd (ENTX)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Miranda J. Toledano
Employees:
20
KIRYAT HADASSAH, MINRAV BUILDING, FIFTH FLOOR, JERUSALEM, ISRAEL 9112002
972-2-532-7151

Entera Bio Ltd. focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism.

Data derived from most recent annual or quarterly report
Market Cap 20.89 Million Shares Outstanding28.814 Million Avg 30-day Volume 47.36 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS0.4
Price to Revenue506.3562 Debt to Equity0.0 EBITDA-11.271 Million
Price to Book Value3.3154 Operating Margin-17263.6364 Enterprise Value22.729 Million
Current Ratio7.612 EPS Growth-0.2 Quick Ratio7.175
1 Yr BETA 0.0252 52-week High/Low 1.48 / 0.47 Profit Margin-17389.3939
Operating Cash Flow Growth19.2301 Free Cash Flow to Firm (FCFF) TTM -7.729 Million Free Cash Flow to Equity (FCFE) TTM-8.011 Million
Altman Z-Score-0.8389
View SEC Filings from ENTX instead.

View recent insider trading info

Entera Bio Ltd YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding ENTX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ENTX

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-09-14 by TAITEL HAYA
  • 4: filed on 2023-09-14 by TOLEDANO MIRANDA JAYNE
  • 4: filed on 2023-08-24 by TAITEL HAYA
  • 3: filed on 2023-08-24 by TAITEL HAYA
  • 4: filed on 2023-08-22 by ELLIS SEAN
  • 4: filed on 2023-04-25 by SANTORA ARTHUR C II
  • 4: filed on 2023-04-25 by YAACOV-GARBELI DANA
  • 4: filed on 2023-04-25 by GALITZER HILLEL
  • 4: filed on 2023-01-04 by GARCEAU ROGER
  • 4: filed on 2023-01-04 by LIEBERMAN GERALD M

    • Events (8k)

  • 8-K: filed on 2023-09-13:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2023-08-11:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-06-30:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  • 8-K: filed on 2023-06-27:
    Item 8.01: Other Events
  • 8-K: filed on 2023-06-07:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2023-05-05:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-31:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-23:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  • 8-K: filed on 2022-11-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-06:
    Item 8.01: Other Events

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    78 Thousand total shares from 3 transactions

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    TOLEDANO MIRANDA JAYNE CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 0 2023-09-13 3

    TAITEL HAYA

    • Director
    		 0 2023-09-13 3

    LIEBERMAN GERALD M

    • Director
    		 220,409 2023-08-21 3

    ELLIS SEAN

    • Director
    		 102,100 2023-08-21 3

    GALITZER HILLEL CHIEF OPERATING OFFICER

    • Officer
    		 0 2023-04-24 1

    SANTORA ARTHUR C II CHIEF MEDICAL OFFICER

    • Officer
    		 0 2023-04-24 1

    YAACOV-GARBELI DANA CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2023-04-24 2

    GARCEAU ROGER

    • Director
    		 89,041 2023-01-02 1

    OSTROV GERALD M

    • Director
    		 89,041 2023-01-02 1

    MAYRON RON

    • Director
    		 89,041 2023-01-02 1

    MALCA YONATAN

    • Director
    		 89,041 2023-01-02 1

    SCHWARTZ PHILLIP PRESIDENT OF R&D

    • Officer
    • Director
    		 607,410 2022-01-20 0

    RATAN RAMESH U.S.BASED CFO

    • Officer
    		 10,000 2022-01-19 0

    JAMAS SPIROS CHIEF EXECUTIVE OFFICER

    • Officer
    		 10,000 2022-01-18 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    TOLEDANO MIRANDA JAYNE - Director - Officer CHIEF EXECUTIVE OFFICER

    		2023-09-14 17:02:48 -0400 2023-09-13 A 350,000 a 350,000 direct

    TAITEL HAYA - Director

    		2023-09-14 17:03:38 -0400 2023-09-13 A 33,368 a 33,368 direct

    TAITEL HAYA - Director

    		2023-08-24 08:12:23 -0400 2023-08-22 P 18,000 $0.62 a 18,000 direct -9.7368 -9.2105 0.0 1 -12.1053 5

    ELLIS SEAN - Director

    		2023-08-22 09:20:56 -0400 2023-08-21 P 40,000 $0.60 a 102,100 direct 5.5882 2.2059 11.7647 3 0.0 1

    LIEBERMAN GERALD M - Director

    		2023-08-23 09:28:13 -0400 2023-08-21 P 20,000 $0.59 a 214,209 direct 5.8496 -6.9638 5.8496 2 -6.9638 6

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ENTERA BIO LTD ENTX 2023-09-29 22:15:03 UTC -11.2783 16.5983 850000
    ENTERA BIO LTD ENTX 2023-09-29 21:45:04 UTC -11.2783 16.5983 850000
    ENTERA BIO LTD ENTX 2023-09-29 21:15:03 UTC -11.2783 16.5983 850000
    ENTERA BIO LTD ENTX 2023-09-29 20:45:05 UTC -11.2783 16.5983 850000
    ENTERA BIO LTD ENTX 2023-09-29 20:15:04 UTC -11.2783 16.5983 850000
    ENTERA BIO LTD ENTX 2023-09-29 19:45:04 UTC -11.2783 16.5983 850000
    ENTERA BIO LTD ENTX 2023-09-29 19:15:03 UTC 0.0 0.0 850000
    ENTERA BIO LTD ENTX 2023-09-29 18:45:03 UTC 0.0 0.0 850000
    ENTERA BIO LTD ENTX 2023-09-29 18:15:03 UTC 0.0 0.0 850000
    ENTERA BIO LTD ENTX 2023-09-29 17:45:03 UTC -11.2783 16.5983 850000
    ENTERA BIO LTD ENTX 2023-09-29 17:15:04 UTC -11.2783 16.5983 850000
    ENTERA BIO LTD ENTX 2023-09-29 16:45:04 UTC -11.2783 16.5983 850000
    ENTERA BIO LTD ENTX 2023-09-29 16:15:03 UTC -11.2783 16.5983 850000
    ENTERA BIO LTD ENTX 2023-09-29 15:45:04 UTC -11.2783 16.5983 850000
    ENTERA BIO LTD ENTX 2023-09-29 15:15:04 UTC -11.2783 16.5983 850000
    ENTERA BIO LTD ENTX 2023-09-29 14:45:04 UTC -11.2783 16.5983 850000
    ENTERA BIO LTD ENTX 2023-09-29 14:15:04 UTC -11.2783 16.5983 850000
    ENTERA BIO LTD ENTX 2023-09-29 13:45:03 UTC -11.1277 16.4477 850000
    ENTERA BIO LTD ENTX 2023-09-29 13:15:04 UTC -11.1277 16.4477 850000
    ENTERA BIO LTD ENTX 2023-09-29 12:45:05 UTC -11.1277 16.4477 850000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments